Last reviewed · How we verify
CL184
CL184 is a vaccine that targets an unspecified pathogen.
CL184 is a vaccine that targets an unspecified pathogen. Used for Unspecified infectious disease prevention.
At a glance
| Generic name | CL184 |
|---|---|
| Sponsor | Crucell Holland BV |
| Modality | Biologic |
| Phase | Phase 2 |
Mechanism of action
The exact mechanism of action of CL184 is not well understood, but it is believed to stimulate an immune response against the targeted pathogen.
Approved indications
- Unspecified infectious disease prevention
Common side effects
- Injection site reactions
- Fever
- Headache
Key clinical trials
- Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults (PHASE2)
- Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents (PHASE2)
- A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |